Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Composition and role of the vacuolar transporter chaperone complex in polyphosphate synthesis and infectivity in <i>Trypanosoma cruzi</i>.

mBio·2026

Same author

Imaging Ca<sup>2+</sup> Signaling in Trypanosoma cruzi with Genetically Encoded Ca<sup>2+</sup> Indicators.

Methods in molecular biology (Clifton, N.J.)·2026

Same author

Selenocyanate-Containing Molecules as Trypanosoma cruzi Inhibitors: Impact of Regioisomerism, Conformational Restriction, and Second-Ring Substitution.

ChemMedChem·2025

Same author

Chemical and Genetic Validation of an Essential Calcium Entry Channel of <i>Trypanosoma brucei</i> as a Therapeutic Target.

ACS infectious diseases·2025

Same author

Lysosome and plasma membrane Piezo channels of Trypanosoma cruzi are essential for proliferation, differentiation and infectivity.

PLoS pathogens·2025

Same author

Generation of inositol polyphosphates through a phospholipase C-independent pathway involving carbohydrate and sphingolipid metabolism in <i>Trypanosoma cruzi</i>.

mBio·2025

Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026

Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026

Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026

Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026

Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026

Same journal

A step toward streamlining HIT diagnosis.

Blood·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 20, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Polyphosphate: a target for thrombosis attenuation.

Roberto Docampo¹

¹UNIVERSITY OF GEORGIA.

|November 22, 2014

Summary

This summary is machine-generated.

Synthetic polyphosphate (polyP) inhibitors effectively reduced thrombosis in mice. These novel compounds offer a promising alternative to heparin, showing reduced bleeding risks in preclinical models.

More Related Videos

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

Related Experiment Videos

Last Updated: Apr 20, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

Area of Science:

Hematology
Pharmacology

Background:

Thrombosis poses a significant clinical challenge, necessitating effective anticoagulant therapies.
Current anticoagulants like heparin carry risks of excessive bleeding.
Polyphosphate (polyP) is implicated in coagulation pathways.

Purpose of the Study:

To evaluate the efficacy of synthetic polyphosphate (polyP) inhibitors in reducing thrombosis.
To assess the safety profile of these inhibitors concerning bleeding complications.

Main Methods:

Administration of synthetic polyphosphate (polyP) inhibitors to mouse models of thrombosis.
Evaluation of antithrombotic activity.
Assessment of bleeding propensity compared to a control group and heparin treatment.

Main Results:

Synthetic polyphosphate (polyP) inhibitors demonstrated a significant reduction in thrombosis.
The inhibitors exhibited a lower propensity to increase bleeding compared to heparin.
Preclinical data suggest a favorable efficacy-safety balance.

Conclusions:

Synthetic polyphosphate (polyP) inhibitors represent a potential new class of antithrombotic agents.
These compounds may offer an improved therapeutic window over existing anticoagulants.
Further investigation is warranted to explore their clinical applicability.